Teva Receives Court Ruling Awarding Exclusivity For Generic Risperdal(R)

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the District of Columbia has granted a request of the Company’s subsidiary, Teva Pharmaceuticals USA, Inc. that the U.S. Food and Drug Administration (FDA) relist in the Orange Book U.S. Patent No. 5,158,952 and grant Teva 180-day exclusivity for a generic version of Janssen Pharmaceutical’s Risperdal® (Risperidone) Tablets. Teva expects final approval with exclusivity on June 29, 2008.

More: continued here

Filed under: Schizophrenia on April 17th, 2008